C-Phycocyanin (C-PC)
(Synonyms: C-藻蓝蛋白; C-PC) 目录号 : GC33095
C-藻蓝蛋白（C-PC）是一种蛋白质色素，也被广泛用作人类优良的营养补充剂。
Cas No.:11016-15-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C-phycocyanin is a water-soluble protein pigment which is also widely used as an excellent nutrient supplement for human beings.
For the combination experiments, when cells treated with All-trans retinoic acid (ATRA) combined with C-phycocyanin, the IC50 value is lower than that in ATRA group. But under the same IC50, the more C-phycocyanin is used, the less ATRA is needed. Results demonstrate that C-phycocyanin combined with ATRA can significantly decrease CDK-4 mRNA level (P<0.05). The combination index (CI) value of the C-phycocyanin+ATRA combination group is 0.852 which is less than 1, indicating that the two drugs are synergetic under the action concentration (88 μg/L C-phycocyanin+0.102 mM ATRA). Compare with control group, the Integrated optical density (IOD) in C-phycocyanin or ATRA treated group is increased, and the differences are statistically significant (P<0.05) and the differences are further exaggerated in combination group (P<0.01). The expression of caspase-3 in C-phycocyanin group is more than that in the control group but is similar to that in ATRA group, whereas the expression in combination group is maximum[1].
Compare with control group, the average tumor weights of mice in solely C-phycocyanin or ATRA treatment groups are significantly decreased, and further reduced in C-phycocyanin+ATRA synergy group. Results show that single C-phycocyanin can increase the spleen weight of mice but the effects of ATRA are just opposite. C-phycocyanin can also promote the growth of immune organs in mice and increase the body's immune function. C-phycocyanin and ATRA alone can significantly inhibit Cyclin D1 expression, and when being combined, the inhibitory effect is more obvious[1].
[1]. Li B, et al. The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo. Eur J Pharmacol. 2015 Feb 15;749:107-14.
Cell experiment: | A549 cells are divided into four groups: (1) control group: the cells are not treated with any drug. (2) C-phycocyanin (C-PC) treated group: the cells are treated with C-phycocyanin alone. (3) All-trans retinoic acid (ATRA) treated group: the cells were treated with ATRA alone. (4) C-phycocyanin+ATRA combined group: the cells are treated simultaneously with C-phycocyanin and ATRA. For the combined treatment group, the combination index (CI) between two drugs is calculated. CI values of less than, equal to, and more than 1 indicate synergy, additivity, and antagonism, respectively[1]. |
Animal experiment: | A total of 40 adult NU/NU mice (20 males and 20 females, 20 to 22 g) are used for the study. The mouse tumor models are set up by subcutaneous injection of 2×106 A549 cells near the armpit area. Fifteen days later, the mice are randomly divided into four groups: control group, All-trans retinoic acid (ATRA) treatment group which is treated with 0.2 mL ATRA (10 mM), C-phycocyanin treatment group which is given 0.2 mL C-phycocyanin (320 mg/mL), and C-phycocyanin+ATRA treatment group receiving 0.2 mL C-phycocyanin (320 mg/mL) and 0.2 mL ATRA (10 mM) at the same time. These agents are injected into the area of tumors and the duration of drug treatment is 10 days. Two days after drug withdrawal, the mice are executed, and then tumors and spleens are picked out[1]. |
References: [1]. Li B, et al. The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo. Eur J Pharmacol. 2015 Feb 15;749:107-14. | |
| Cas No. | 11016-15-2 | SDF | |
| 别名 | C-藻蓝蛋白; C-PC | ||
| Canonical SMILES | [C-Phycocyanin] | ||
| 分子式 | 分子量 | ||
| 溶解度 | Water : 14.29 mg/mL | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet